Phase I/II study of Gemcitabine and S-1 (GS therapy) as Neoadjuvant chemoradiationtherapy for borderline resectable pancreatic cancer (Prep-03/NS014-1)
Phase 1
Recruiting
- Conditions
- Borderline resectable pancreatic cancer
- Registration Number
- JPRN-UMIN000014498
- Lead Sponsor
- Study group of preoperative therapy for pancreatic cancer (PREP)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) pulmonary fibrosis or interstitial pneumonitis 2) Active double cancer 3) Active infection 4) HBs antigen positive 5) patients are using flucytosine, phenytoin, warfarin 6) pregnant females, possibly pregnant females
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Phase I:Maximum Tolerated Dose, Recommended Dose Phase II: R0 resection rate
- Secondary Outcome Measures
Name Time Method